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Introduction
Seventy million people have epilepsy, with 34-76 per 100,000 developing the condition every year (Brodie et al., 2012) .
For many years a significant proportion of patients with epilepsy have been treated with polytherapy since initial monotherapy did not result in all patients being seizure free. The widespread use of polytherapy is sustained by the nature of developing new AEDs where newer agents are studied 'on top' of existing therapy to avoid the unethical situation of a patient with epilepsy being without effective therapy, and thus newer AEDs are usually approved as adjunctive therapy (St. Louis, 2009 ).
In recent years the advantages of AED monotherapy have been described; they include easier dosage optimization for a given single agent, lower treatment costs, simpler dosing schedules (expected to improve adherence), reduced likelihood of adverse events, decreased risk of drug-drug interactions and, possibly, lower medication costs (St Louis, 2009; Wechsler et al., 2014) . If a patient is to be weaned onto monotherapy for a particular AED from a polytherapy situation, then it is critical to understand what dosage modifications may be needed for the intended monotherapy agent as the remaining polytherapy agents are withdrawn. Whether or not a separate monotherapy indication is warranted for AEDs has been discussed by Mintzer et al., (2015) who concluded that the regulatory requirement for separate monotherapy and adjunctive therapy indications in epilepsy were unnecessarily restrictive.
The same authors recommended that regulatory agencies should approve AEDs for the treatment of specific seizure types or epilepsy syndromes, irrespective of concomitant drug use.
Brivaracetam (UCB34714) is a selective, high-affinity synaptic vesicle protein 2A (SV2A) ligand (Klitgaard et al., 2016 ) that was recently approved as adjunctive therapy in the treatment of focal (partial-onset) seizures in patients 16 years of age and older with epilepsy (French et al., 2010a; Van Paesschen et al., 2013; Biton et al., 2014; Ryvlin et al., 2014; Klein et al., 2015) . Brivaracetam is rapidly and highly absorbed and peak plasma concentrations are generally reached within 1 hour after dosing in fasting healthy volunteers . The disposition of brivaracetam is characterized by linear pharmacokinetics over a large range of doses (10 to 600 mg) (Sargentini-Maier et al., 2007) . Brivaracetam is eliminated primarily by metabolism, which is partially cytochrome P450 dependent. The three main metabolites are not pharmacologically active. Only a small fraction (up to 10%) of the dose is excreted as parent compound in the urine (Sargentini-Maier et al., 2008) . The potential for interference with brivaracetam metabolism through inhibition of cytochrome P450 mediated metabolism is low (Stockis et al., 2014) ; this is supported by the results from a population pharmacokinetic analysis where it was found that co-administration of brivaracetam with carbamazepine, phenytoin, and phenobarbital decreased brivaracetam exposure by 26%, 21%, and 19% (Schoemaker et al., 2016) .
The objective of the present analyses was to describe the population pharmacokinetics and pharmacodynamics (effect on seizure frequency) of brivaracetam in different adjunctive treatment settings and in monotherapy, and to use these results to guide the selection of brivaracetam doses in monotherapy. The data originated from three Phase III add-on trials and two terminated Phase III conversion to monotherapy trials in refractory adult patients with focal seizures. The current analysis included extending an existing brivaracetam population pharmacokinetic model (Schoemaker et al., 2016) so it could quantify the effect of AED coadministration on the clearance of brivaracetam. Subsequently, a previously published brivaracetam exposure-response model that described the adjunctive brivaracetam exposureresponse in refractory adult patients with focal seizures (Schoemaker et al., 2016) was updated to incorporate the effects on response of co-administration of common AEDs.
The updated exposure-response model was then used to quantify and simulate the effect of AED co-administration. The overall aim of the analyses was to provide dosing suggestions for brivaracetam use as monotherapy.
Materials and Methods
The studies were conducted in accordance with the International Council on Harmonization notes for Guidance on Good Clinical Practice and the Declaration of Helsinki.
The study protocols were approved by institutional review boards at all study sites, and written informed consent was obtained from all patients before enrolment.
Data
The brivaracetam plasma concentration and demographic data from three Phase III add-on trials N01252 (NCT00490035) (Ryvlin et al., 2014) , N01253 (NCT00464269) (Biton et al., 2014) and N01358 (NCT01261325) (Klein et al., 2015) were combined with data from two Phase III conversion to monotherapy trials N01276 (NCT00698581) and N01306 (NCT00699283) (Mula, 2016) .
The design of the three add-on-trials has been summarized by Ben-Menachem (BenMenachem et al., 2016) . The two conversion to monotherapy trials N01276 and N01306
were double-blind, therapeutic confirmatory, randomized, multi-center, parallel-group, historical-controlled conversion to monotherapy studies to evaluate the efficacy and safety of brivaracetam in patients (aged from 16 to 75 years) with focal seizures with or without secondary generalization. The primary objective of these studies was to evaluate the efficacy of brivaracetam in conversion to monotherapy at doses of 50 and 100 mg/day (administered in two equal doses per day) when compared to a historical control group (French et al., 2010b) .
The trial consisted of a baseline period of 8 weeks during which time patients remained on a stable dose of 1-2 AEDs. After successful completion of the baseline period patients were randomized to either brivaracetam 50 mg/day or brivaracetam 100 mg/day in a 3:1 ratio. After randomization, patients remained on their current dose of baseline AED in parallel to the randomized dose of brivaracetam for one week to assure that brivaracetam had reached steady-state before starting tapering of the baseline AED. The subsequent 16-week evaluation period consisted of 8 weeks baseline AED down-titration followed by 8 weeks brivaracetam monotherapy. Finally, a 6-week reconversion period or inclusion into a long-term follow-up study was foreseen. Criteria were set to allow early discontinuation. Two blood samples with at least a 15-minute interval were to be collected at two visits.
A summary of the design of the five studies included in the present analyses is given in Table 1 .
The population pharmacokinetic data set contained 4928 brivaracetam concentrations from 1101 patients; among these, 453 concentrations in 141 patients came from the two conversion to monotherapy trials, of which 122 concentrations came from 64 patients achieving monotherapy. Focal seizure count data were available from 1549 patients in the three add-on trials (including 318 on placebo) who contributed 217,524 daily seizure counts.
Software and hardware
The analyses were performed using NONMEM Version 7.2.0 (Beal et al., 1989 (Beal et al., -2009 software, supplemented with the PsN toolkit (Lindbom et al., 2005) , and were further processed using 64 bit R Version 3.1.2 software (R Development Core Team, 2014).
Pharmacokinetic data were analyzed using First Order Conditional Estimation with the Interaction option; seizure count data were analyzed using the Laplacian estimation method.
Simulations were performed using R and NONMEM.
Population pharmacokinetic model
The previously published population pharmacokinetic model (Schoemaker et al., 2016) found that brivaracetam was well described using a one-compartment model with firstorder absorption. Clearance (CL) and volume (V) were influenced by body weight using an allometric relationship, and CL was influenced by concomitant hepatic enzyme-inducing AEDs. This model was applied to the current data set, and the following concomitant drugs were tested for their potential effect on CL:
• CBZ carbamazepine
• PHT phenytoin
• PB phenobarbital or primidone
• VPA valproate
• LTG lamotrigine
• LEV levetiracetam
• OXC oxcarbazepine
• TPM topiramate
• BENZC benzodiazepines chronically prescribed for the indication 'epilepsy'
• LCM lacosamide
• PGN pregabalin
• ZNS zonisamide
All drug effects on CL were simultaneously estimated, and no further covariates were assessed.
The updated brivaracetam population pharmacokinetic model with concomitant drug effects was used to generate daily average concentration (Cav) estimates for use in the exposure-response modeling. The generated daily Cav estimates reflected a given patient's actual dosing history, and as such could change from day to day. For patients with no brivaracetam concentrations (n=130), Cav was obtained using the typical population pharmacokinetic model parameters and those patients' specific covariate influences.
Concentration-daily seizure rate frequency model
The present exposure-response analysis was restricted to the Phase III add-on trials only. If effects were found of concomitant AEDs on the concentration-effect relationship of brivaracetam, monotherapy efficacy predictions can be obtained by removing these effects from the model. The current model assumes constant concomitant AED therapy, and temporal changes in brivaracetam concentrations is the only factor to describe temporal changes in seizure frequencies. Applying the model to the monotherapy study data would require concentration-effect models and concentration-time profiles of the different AEDs, and models to describe the combined effect of brivaracetam and these AEDs. These models and concentration-time profiles were not available, and would require a far more complex model than the data could support. Therefore daily seizure counts for the monotherapy trials were not included in the analysis.
The Cav-daily seizure count relationship was estimated based on the model structure described previously (Schoemaker et al., 2016) . Since daily Cav was used as a measure for exposure, this allowed an independent assessment of the concomitant AED effects on pharmacokinetics (by changing the daily exposure to brivaracetam), as well as on the exposure-response relationship (by changing the efficacy of brivaracetam in the presence of concomitant AEDs).
Count models were used to describe daily seizures where seizure rates were a function of both placebo and drug, and the occurrence of seizures on the previous day (a 'Markovian aspect'). During model development it became apparent that a fraction of the patients were following a daily seizure pattern very similar to those receiving placebo, while another fraction of patients was associated with much larger and dose-dependent decreases from baseline. This concept was implemented by assuming two populations, the first where a concentration-dependent decrease in seizure frequency was added onto the placebo distribution, and the second with a placebo-like response, governed only by the placebo model-parameter. NONMEM estimated the probability for a patient to end up in one of the two populations (P1). The first population was denoted as the 'mixture-model responder population' and the second as the 'mixture-model placebo-like population' (Schoemaker et al., 2016) .
A visual predictive check (VPC, Karlsson and Holford, 2008) was performed to investigate if model simulations of daily seizure counts corresponded to observed trial outcomes for the entire population, split by administered dose. Seizure counts were simulated 500 times using the trial structure, dose and covariate data from the patients in the data set.
The potential influence on the pharmacodynamic effect of brivaracetam of the individual concomitant AEDs, was investigated on the EC50 of the concentration-effect relationship, and on the parameter describing the probability of being in the 'mixture-model responder population'. For benzodiazepines, only those chronically administered for epilepsy treatment were investigated, since these drugs are frequently prescribed as rescue medication, and may therefore be confounded with cases of potentially high seizure frequency.
Monotherapy dose simulations
The obtained pharmacokinetic and exposure-response (Cav-daily seizure count) models were used to simulate the effects on pharmacokinetics and on change in seizure counts under the full concomitant AED therapy profile, and under the situation corresponding to monotherapy where the estimated AED effects were removed from the model.
For the pharmacokinetic simulations, all patients included in the analysis were taken with their concomitant AED covariates. These were combined with fixed weight steps of 10 kg, ranging from 40 to 130 kg, and pharmacokinetic parameters were subsequently sampled from the distributions described by the NONMEM parameter estimates for the final pharmacokinetic model. Cav was calculated for a 100 mg/day steady-state dose, both by assuming the presence of the full concomitant AED profile, and by removing the AED effects, corresponding to the monotherapy situation.
For the daily seizure count simulations, all patients in the analysis were taken with their concomitant AED and baseline weight covariates. Pharmacokinetic parameters were subsequently sampled from the distributions described by the NONMEM parameter estimates for the final pharmacokinetic model, and Cav was calculated for steady-state doses of 0, 25, 50, 100, 150 and 200 mg/day, both by assuming the presence of the full concomitant AED profile, and by removing the AED effects (corresponding to the monotherapy situation).
These Cav values were then combined with a trial structure consisting of 8 weeks of daily seizure count assessments at baseline followed by 12 weeks' treatment, and the simulated Cav values were assumed to drive the effect, again both by assuming the presence of the full concomitant AED profile, and by removing the AED effects on the pharmacodynamics, corresponding to the monotherapy situation. Mean seizure frequencies were calculated for each simulated patient and dose combination for the entire baseline and treatment periods, for both adjunctive therapy and for monotherapy. what has been published previously (Schoemaker et al., 2016) . Since enzyme-inducing AED co-administration is widespread (50.5% of the population in this data set), monotherapy was estimated to lead to a 22.6% higher population Cav for a 70 kg patient when compared with the add-on trial results.
Results and Discussion

Population pharmacokinetic model
The fold changes in Cav associated with AED co-administration estimated for all AED and drug class covariates were summarized in a forest plot. As the forest plot was very similar to the one previously generated (Schoemaker et al., 2016) , it is only provided in the online supplement as Figure S1 . The relatively low increase in median Cav for a patient receiving 
Concentration-daily seizure rate frequency model
Inspection of the graphs generated to guide the choice for the shape of the relationship between Cav and seizure rate (Figure 1) ) revealed both the large variability in response between patients (left panel) and the potential shape of the exposure-response curve using a locally weighted scatterplot smoothing (LOESS) through the data (right panel). An Emax-type relationship seemed most appropriate.
Development of the concentration-daily seizure rate model focused on detecting AED co-administration covariate effects, and started with the structural model without covariates (Schoemaker et al., 2016) , which had utilized an Emax-type relationship for the 'mixturemodel responder population'. When the potential effects of the background AED and log baseline seizure frequency on the probability of being in the 'mixture-model responder population' were estimated they revealed that log baseline seizure frequency, and levetiracetam and valproate co-administration all affected the probability of being in the 'mixture-model responder population'. None of the AED covariates was found to influence EC50 (estimated to be 0.548 mg/L), the population-typical average daily concentration associated with reaching 50% of the maximum effect. The parameter estimates of all parameters in the final concentration-daily seizure rate model were very similar to the ones previously generated (Schoemaker et al., 2016) , and are therefore only provided in the online supplement as Table S1 .
The probabilities for being in the 'mixture-model responder population' as a function of log baseline seizure frequency were estimated to be 52.2% at 1 seizure/week, 27.1% at 0.32 seizures/day (median baseline seizure frequency), and 0.8% at 6 seizures/day. Levetiracetam co-administration was estimated to reduce the probability of being in the 'mixture-model responder population' at median baseline seizure frequency from 27.1% to 4.2%. Since levetiracetam and brivaracetam have a similar mode of action, the presence of levetiracetam likely precludes brivaracetam from inducing additional seizure reduction effects.
Coadministration with valproate was associated with an estimated increase in the probability for being in the 'mixture-model responder population' from 27.1% to 39.1%. Whether this increase is due to a deviating sub-population of patients receiving valproate treatment, or due to an increased sensitivity to brivaracetam with the co-administration of valproate, is unclear.
Model evaluation for the final concentration-daily seizure rate count model was done using VPCs and is provided in the online supplement. VPCs for the derived parameters of median percent change from baseline in seizure frequency, and fraction of ≥50% responders defined as patients experiencing at least 50% decrease from baseline in seizure frequency (online supplement Figure S2) , and a VPC of seizure frequency change over time for the different doses (online supplement Figure S3 ) illustrated that the final model was able to simulate the various study outcome measures.
Monotherapy dose simulations
The 5 
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